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Proliferating cells such as tumor cells have increased
metabolic demands that include ATP, NADPH, lipids,
proteins, and nucleotides to allow for a tumor cell to
divide into two daughter cells [1]. Tumor cells repro-
gram their cell metabolism to sustain the increased
metabolic demands of cell proliferation. Historically,
much attention has focused on glycolysis as the central
metabolic pathway important for tumor cell metabol-
ism, an idea that stems from the observation made in
1920s by Otto Warburg that tumor slices consume glu-
cose at a higher rate than normal tissue slices at nor-
mal oxygen levels [2]. This high rate of aerobic glycolysis
is known as the Warburg effect and can be observed in
proliferating tumor cells of cancer patients by the high up-
take of the glucose analogue tracer 18-fluorodeoxyglucose
(FDG) detected by Positron Emission Tomography (PET)
technology [3]. The basis and the advantage of the
Warburg effect for proliferating cells such as cancer
cells had not been fully resolved until recently.
Today, there is consensus that combination of gain
of function of oncogenes, loss or tumor suppressor and
aberrant activation of signaling pathways downstream
of growth factor signaling induce the Warburg effect
[4]. This increase in glucose metabolism through gly-
colysis allows the generation of glycolytic interme-
diates that funnel into biosynthetic pathways that
support the production of NADPH, lipids, proteins
and nucleotides [5]. However, the biochemists working
on cancer metabolism decades ago realized that glu-
cose metabolism alone could not fully support the de
novo production of NADPH, ATP, lipids, nucleotides
and proteins required for cell proliferation. Today, it is
appreciated that mitochondrial metabolism is also essen-
tial for building blocks needed for cell proliferation. For
example, phospholipid generation needed for de novo
cell membranes in proliferating cells requires fatty acids
and glycerol. The glycolytic intermediate dihydroxyacetoneCorrespondence: nav@northwestern.edu
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mediate citrate transports into the cytosol where it is
converted into acetyl-CoA to produce fatty acids. As
glucose is the fuel for glycolysis and its subsidiary bio-
synthetic pathways, glutamine has emerged as a key fuel
for mitochondrial metabolism [6]. A consequence of
mitochondrial oxidative metabolism is the generation of
reactive oxygen species (ROS) that are necessary for op-
timal activation of signaling pathways needed for cell
proliferation [7]. Recent studies have confirmed previ-
ous work indicating that the majority of ATP in tumor
cells is derived from mitochondrial oxidative phosphor-
ylation [8].
It is important to note that mitochondria are indeed
functional in most tumor cells. However, there are a
fraction of tumor cells that have been shown to exhibit
mitochondrial dysfunction due to loss of function muta-
tions in the TCA cycle enzymes succinate dehydrogenase
(SDH) or fumarate hydratase (FH) [9]. These cells rely
on glycolysis for ATP production. However, SDH and
FH null cells are still dependent on the fraction of mito-
chondrial TCA cycle and ETC. that is functional in these
cells to generate TCA cycle intermediates such as citrate
for macromolecule synthesis and ROS for signaling.
Thus, mitochondria contribute to the bioenergetic, bio-
synthetic and signaling requirements of proliferating
cancer cells. A recent bioinformatics analysis yielded en-
zymes in mitochondrial one-carbon metabolic pathways
as the top hits of metabolic enzymes upregulated in can-
cer compared to normal proliferating cells [10]. Interest-
ingly, the anti-diabetic drug metformin, which has been
repurposed as an anti-cancer agent, was recently shown
to inhibit mitochondrial complex I to exert its’ anti-
tumorigenic properties [11]. Collectively these insights
have led to the possibility of targeting mitochondria for
cancer therapy. In this series on mitochondria and can-
cer, the diverse functions and regulators of mitochondria
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